Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Company XYZ (Ticker: XYZ) Reports Total Number of Voting Rights and Shares as of November 30, 2023
Positive
- None.
Negative
- None.
Information regarding the total number of voting rights and
total number of shares of the Company as of November 30, 2023
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 11/30/2023 | 96,431,770 | Total gross of voting rights: 96,431,770 |
| Total net* of voting rights: 96,186,256 |
* Net total = total number of voting rights attached to shares – shares without voting rights
Attachment
FAQ
What is the ISIN Code for Company XYZ on NYSE Euronext Paris?
The ISIN Code for Company XYZ on NYSE Euronext Paris is FR 0010417345.
How many total shares does Company XYZ have as of November 30, 2023?
As of November 30, 2023, Company XYZ has a total of 96,431,770 shares.
What is the total number of voting rights for Company XYZ as of November 30, 2023?
As of November 30, 2023, Company XYZ has a total gross of 96,431,770 voting rights and a net of 96,186,256 voting rights.
What is the significance of the total net voting rights for Company XYZ?
The net total of voting rights for Company XYZ is calculated as the total number of voting rights attached to shares minus the shares without voting rights.
DBV Technologies S.A.
NASDAQ:DBVT
DBVT Rankings
DBVT Latest News
DBVT Stock Data
129.22M
43.83M
19.64%
0.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
MONTROUGE
About DBVT
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and